<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01054586</url>
  </required_header>
  <id_info>
    <org_study_id>111949</org_study_id>
    <secondary_id>WEUKSTV2430</secondary_id>
    <secondary_id>EPI40537</secondary_id>
    <nct_id>NCT01054586</nct_id>
  </id_info>
  <brief_title>Fosamprenavir in Pts With Hepatic Impairment</brief_title>
  <official_title>HI FPV Study: Using Observational Cohorts to Monitor Safety of Fosamprenavir in Patients With Mild/Moderate Hepatic Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      APV10017 was a pharmacokinetic study that evaluated the pharmacokinetics, safety and
      tolerability of fosamprenavir/ritonavir (FPV/RTV) at reduced doses over 14 days in
      HIV-infected subjects with mild to moderate hepatic impairment (HI). Based on these data, two
      new regimens have recently been approved by the EMEA and FDA in these patient groups; FPV
      700mg BID/RTV 100mg QD for those with mild HI (Child-Pugh score 4-6) and FPV 450mg BID/RTV
      100mg QD for those with moderate HI (Child Pugh score 7-9). The Committee for Medicinal
      Products for Human Use (CHMP) has requested longer-term safety data among this hepatically
      impaired HIV-infected population who have received the recently updated FPV/RTV dosing
      regimens.

      An observational cohort study will be conducted using routinely collected data in three
      European HIV patient cohorts with a high proportion of hepatitis co-infected individuals.
      Patients who received FPV/RTV will be followed to address the following objectives.

      Primary: To assess the safety and tolerability of FPV/RTV-based ART in subjects with mild to
      moderate hepatic impairment.

      Secondary: A). To compare the safety and tolerability of FPV/RTV-based ART in subjects with
      mild to moderate hepatic impairment when compared to FPV/RTV-based ART in hepatitis B (HBV)
      or hepatitis C (HCV) co-infected subjects with normal hepatic function. B). To compare the
      safety and tolerability of FPV/RTV-based ART to lopinavir/ritonavir LPV/RTV-based ART in
      subjects with mild to moderate hepatic impairment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients were not recruited for nor enrolled in this study. This study is a retrospective
      observational study. Data from medical records or insurance claims databases are anonymised
      and used to develop a patient cohort. All diagnoses and treatment are recorded in the course
      of routine medical practice.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Events of ALT Elevation After Baseline, Controlling for APRI Score and Other Variables</measure>
    <time_frame>The incidence of these events was assessed over time during Year 1, censoring participants' follow-up at date of last ALT</time_frame>
    <description>An elevation in ALT is defined as a single value &gt;200 IU/I.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Events of an Elevation in ALT After Baseline by Treatment Group, Controlling for APRI-score, and Other Variables</measure>
    <time_frame>Incidence of these events was assessed over time during Year 1, censoring patients' follow-up at date of last ALT</time_frame>
    <description>An elevation in ALT is defined as a single value &gt;200 IU/I.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Events of an Elevation in ALT After Baseline by Treatment Group, Controlling for FIB-score, and Other Variables</measure>
    <time_frame>Incidence was assessed over time during Year 1</time_frame>
    <description>An elevation in ALT is defined as a single value &gt;200 IU/I.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Events of an Elevation in ALT After Baseline by Treatment Group, Controlling for Current Values of CD4 and Platelet Counts</measure>
    <time_frame>Incidence was assessed over time during Year 1</time_frame>
    <description>An elevation in ALT is defined as a single value &gt;200 IU/I.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Events of First Discontinuation of FPV/RTV or LPV/RTV Alone by Treatment Group, Controlling for APRI-score, and Other Variables</measure>
    <time_frame>Incidence was assessed over time during Year 1</time_frame>
    <description>A first discontinuation is defined as the first occurrence of stopping FPV/RTV or LPV/RTV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Events of First Discontinuation of FPV/RTV or LPV/RTV Alone by Treatment Group, Controlling for FIB-score, and Other Variables</measure>
    <time_frame>Incidence was assessed over time during Year 1</time_frame>
    <description>A first discontinuation is defined as the first occurrence of stopping FPV/RTV or LPV/RTV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Events of First Discontinuation of FPV/RTV- or LPV/RTV Alone by Treatment Group, Controlling for Current Values of CD4 and Platelet Counts</measure>
    <time_frame>Incidence was assessed over time during Year 1</time_frame>
    <description>A first discontinuation is defined as the first occurrence of stopping FPV/RTV or LPV/RTV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Events of First Discontinuation of FPV/RTV or LPV/RTV Alone Due to Adverse Events Only</measure>
    <time_frame>Incidence was assessed over time during Year 1</time_frame>
    <description>A first discontinuation is defined as the first occurrence of stopping FPV/RTV or LPV/RTV; where the reason for stopping is attritubed to adverse events only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Events of First Discontinuation of One or More Drugs Included in the FPV/RTV- or LPV/RTV-based Regimen by Treatment Group, Controlling for APRI-score and Other Variables (See Comments)</measure>
    <time_frame>Incidence was assessed over time during Year 1</time_frame>
    <description>A first discontinuation is defined as the first occurrence of stopping one or more drugs in the FPV/RTV or LPV/RTV-based regime</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Events of First Discontinuation of One or More Drugs Included in the FPV/RTV- or LPV/RTV-based Regimen by Treatment Group, Controlling for FIB-score and Other Variables</measure>
    <time_frame>Incidence was assessed over time during Year 1</time_frame>
    <description>A first discontinuation is defined as the first occurrence of stopping one or more drugs in the FPV/RTV or LPV/RTV-based regime.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Events of First Discontinuation of One or More Drugs Included in the FPV/RTV- or LPV/RTV-based Regimen by Treatment Group, Controlling Current Values of CD4 and Platelet Counts</measure>
    <time_frame>Incidence was assessed over time during Year 1</time_frame>
    <description>A first discontinuation is defined as the first occurrence of stopping one or more drugs in the FPV/RTV or LPV/RTV-based regime.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Events of Discontinuation of One or More Drugs in the FPV/RTV- or LPV/RTV Regimen Due to Adverse Events Only</measure>
    <time_frame>Incidence was assessed over time during Year 1</time_frame>
    <description>Defined as the occurrence of stopping FPV/RTV or LPV/RTV; where the reason for stopping is attributed to adverse events only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Events of First Discontinuation of FPV/RTV or LPV/RTV Alone Due to the Indicated Adverse Events</measure>
    <time_frame>Incidence was assessed over time during Year 1</time_frame>
    <description>Defined as the first occurrence of stopping FPV/RTV or LPV/RTV; where the reason for stopping is attributed to adverse events only. Adverse events can only be attributed to the body system stated (no further specificity is available).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinued the Indicated Antiretrovirals for the First Time After Starting FPV/r or LPV/r</measure>
    <time_frame>Assessed over time during Year 1</time_frame>
    <description>Antiretrovirals discontinued for the first time after starting FPV/r or LPV/r</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the Indicated Major Reasons for Discontinuing One or More Drugs in the FPV/r or LPV/r Regimen</measure>
    <time_frame>Assessed over time during Year 1</time_frame>
    <description>Major reasons for discontinuing one or more drugs in the FPV/r or LPV/r regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants for Which the Reason for Discontinuation of One or More Drugs in the FPV/RTV or LPV/RTV Regimen Was Due to Adverse Events Only</measure>
    <time_frame>The incidence of these events was assessed over time during Year 1</time_frame>
    <description>Number of participants for which the reason for discontinuation of one or more drugs in the FPV/RTV or LPV/RTV regimen was due to adverse events only. Adverse events can only be attributed to the body system stated (no further specificity is available)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Rates Per 100 Person-years of Follow-up (PYFU) of Study Main Outcome Measures</measure>
    <time_frame>Incidence of these events was assessed over time during Year 1</time_frame>
    <description>Incidence rates per 100 person-years of follow-up of study primary outcome. The numbers analyzed in the category titles represent the number of patients with each event. Incidence rate is the number of new cases per population in a given time period, where the denominator is the sum of the person-time of the at-risk population.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Median Length of Participant Follow-up and Length of Time on Antiretroviral Therapy (ART) at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Participant characteristics at baseline are presented according to treatment group. ART is used for the treatment of HIV.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cluster of Differentiation (CD4) Count at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Participant characteristics at baseline according to treatment group. CD4 count is a measurement of how many functional CD4 T-cells are circulating in the blood. The lower the absolute CD4 count, the weaker the immune system.</description>
  </other_outcome>
  <other_outcome>
    <measure>Median Aspartate Aminotransferase (AST)-Platelet Ratio Index (APRI) Score at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>The APRI score (AST to platelet ratio index) is an index comprised of biochemical values and is used to determine the degree of hepatic fibrosis. It is calculated as follows: APRI score = ([AST level/Upper Limit Normal]/Platelet counts) x 100. AST = Aspartate aminotransferase. In general, APRI scores range from 0 to &gt;2.0, where scores &lt;0.5 indicate no significant fibrosis, scores &gt;1.5 indicate significant fibrosis, and scores &gt;2.0 have been shown to be best correlated with the presence of cirrhosis.</description>
  </other_outcome>
  <other_outcome>
    <measure>Median FIB (a Model of End-stage Liver Disease) Score at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>The FIB-4 score is an index that combines biochemical values (platelets, ALT, AST) and age to determine the degree of hepatic fibrosis. FIB-4 = (Age x AST)/(Platelet counts x ALT1/2). The FIB-4 score ranges between values of 0 to 13. A score of &lt;1.45 indicates no/moderate fibrosis (F0-F1-F2-F3 in the ISHAK classification of fibrosis), whereas a score &gt;3.25 is indicative of extensive fibrosis or cirrhosis (F4-F5-F6). The ISHAK classification of fibrosis is a commonly used scoring system that stages fibrosis from 0-6 (1-2, portal fibrotic expansion; 3-4, bridging fibrosis; 5-6, cirrhosis).</description>
  </other_outcome>
  <other_outcome>
    <measure>Median Model of End-stage Liver Disease (MELD) Score at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>MELD is a scoring system for assessing the severity of chronic liver disease and is used to predict participant survival. It is calculated using biochemical values as follows: MELD = (0.957 x Log[Creatinine]) + (0.378 x Log[Bilirubin]) + (1.120 x Log[INR]) + 0.6431. INR = International Normalized Ratio for prothrombin time. MELD scores range between 0 and 40, with 40 being the most severe, i.e., 100% mortality. In interpreting the MELD score in hospitalized participants, the 3-month mortality is: score &gt;=40, 100% mortality; 30-39, 83% mortality; 20-29, 76% mortality; 10-19, 27% mortality.</description>
  </other_outcome>
  <other_outcome>
    <measure>Median ALT and AST Scores at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Participants characteristics at baseline according to treatment group.</description>
  </other_outcome>
  <other_outcome>
    <measure>Median Blood Platelet Count at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Participant characteristics at baseline according to treatment group.</description>
  </other_outcome>
  <other_outcome>
    <measure>Median Bilirubin Level at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Participant characteristics at baseline according to treatment group.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">167</enrollment>
  <condition>Infection, Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>HIV pts w/ HBV or HCV, w/ or w/o mild to moderate HI</arm_group_label>
    <description>Patients with HIV coinfected with HBV or HCV with or without mild to moderate HI who are enrolled in one of the participating HIV patient cohorts. These patients will be exposed to FPV/RTV or LPV/RTV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intervention A Standard dose</intervention_name>
    <description>HIV subjects with HBV or HCV co-infection but normal hepatic function, defined by receipt of FPV 700mg BID/RTV 100mg BID and a baseline AST-platelet ratio index (APRI) score of &lt;2.0.</description>
    <arm_group_label>HIV pts w/ HBV or HCV, w/ or w/o mild to moderate HI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intervention B Reduced Dose</intervention_name>
    <description>HIV subjects with mild hepatic impairment, defined by receipt of the recommended reduced FPV/RTV dose (700mg BID/100mg QD).</description>
    <arm_group_label>HIV pts w/ HBV or HCV, w/ or w/o mild to moderate HI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intervention C</intervention_name>
    <description>HIV subjects with moderate hepatic impairment, defined by receipt of FPV 450mg BID/RTV 100mg QD.</description>
    <arm_group_label>HIV pts w/ HBV or HCV, w/ or w/o mild to moderate HI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intervention D</intervention_name>
    <description>HIV subjects receiving the standard dose of FPV/RTV despite evidence of abnormal hepatic function according to APRI score: HIV subjects with HBV or HCV co-infection, receipt of FPV 700mg BID/RTV 100mg BID and a baseline APRI score of ≥2.0.</description>
    <arm_group_label>HIV pts w/ HBV or HCV, w/ or w/o mild to moderate HI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intervention E</intervention_name>
    <description>HIV subjects coinfected with HBV or HCV who have initiated standard doses of LPV 400mg/RTV 100mg and enrolled in the same cohorts as the FPV/RTV exposed subjects.</description>
    <arm_group_label>HIV pts w/ HBV or HCV, w/ or w/o mild to moderate HI</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The source population is from three HIV patient cohorts; ICONA, HEPAVIH and MASTER cohort
        in Europe. Data from these cohorts are comprised of the clinical records (or a defined
        subset thereof) of HIV infected patients. The ICONA Foundation study collects data on HIV
        infected individuals from 67 infectious disease centres across Italy and has been
        established since 1997. The ICONA cohort only includes patients who are treatment naïve at
        initial presentation. HEPAVIH is a cohort of HIV-hepatitis co-infected patients, identified
        from three other ongoing French HIV cohorts: RIBAVIC, SEROCO and AQUITAINE and an
        additional 12 clinical departments. The MASTER cohort collects data on HIV infected
        individuals from centres across Italy and includes treatment-experienced and naive
        patients.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV infected patients with or without hepatic impairment coinfected with HBV or HCV
             who started FPV/RTV-based therapy on or after January 1, 2008. The FPV/RTV exposed
             patients will be stratified into four groups for analysis (see interventions A-D for
             label/description above), according to their degree of baseline hepatic impairment,
             which will be defined according to FPV/RTV dose received (and APRI score for
             interventions A and D). The LPV/RTV intervention group must have started this therapy
             at approved standard doses on or after January 1, 2008.

        Exclusion Criteria:

          -  Receipt of FPV/RTV or LPV/RTV within the year preceding the baseline visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2010</study_first_submitted>
  <study_first_submitted_qc>January 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2010</study_first_posted>
  <results_first_submitted>January 14, 2011</results_first_submitted>
  <results_first_submitted_qc>June 2, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 28, 2011</results_first_posted>
  <last_update_submitted>May 2, 2013</last_update_submitted>
  <last_update_submitted_qc>May 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antiretroviral therapy</keyword>
  <keyword>hepatic impairment</keyword>
  <keyword>HIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fosamprenavir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>As this was an observational, retrospective study, no participants were recruited for participation in this study. For more information about this study, see the protocol in ClinicalTrials.gov and/or search for this study (111949) on http://www.gsk-clinicalstudyregister.com/.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>FPV 700 mg BID/RTV 100 mg BID</title>
          <description>Fosamprenavir 700 milligrams (mg) twice a day (BID)/Ritonavir 100 mg BID</description>
        </group>
        <group group_id="P2">
          <title>FPV 700 mg BID/RTV 100 mg QD</title>
          <description>FPV 700 mg BID/RTV 100 mg once a day (QD)</description>
        </group>
        <group group_id="P3">
          <title>FPV, Other</title>
          <description>All other dosages of FPV (excluding FPV 700 mg BID/RTV 100 mg BID and FPV 700 mg BID/RTV 100 mg QD)</description>
        </group>
        <group group_id="P4">
          <title>LPV, Standard Dose</title>
          <description>Lopinavir (LPV), Standard Dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FPV 700 mg BID/RTV 100 mg BID</title>
          <description>Fosamprenavir 700 milligrams (mg) twice a day (BID)/Ritonavir 100 mg BID</description>
        </group>
        <group group_id="B2">
          <title>FPV 700 mg BID/RTV 100 mg QD</title>
          <description>FPV 700 mg BID/RTV 100 mg once a day (QD)</description>
        </group>
        <group group_id="B3">
          <title>FPV, Other</title>
          <description>All other dosages of Fosamprenavir</description>
        </group>
        <group group_id="B4">
          <title>LPV, Standard Dose</title>
          <description>Lopinavir (LPV), Standard Dose</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="101"/>
            <count group_id="B5" value="167"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" lower_limit="36" upper_limit="62"/>
                    <measurement group_id="B2" value="45" lower_limit="29" upper_limit="51"/>
                    <measurement group_id="B3" value="44" lower_limit="36" upper_limit="53"/>
                    <measurement group_id="B4" value="44" lower_limit="25" upper_limit="74"/>
                    <measurement group_id="B5" value="44" lower_limit="25" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="63"/>
                    <measurement group_id="B5" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cohort Distribution</title>
          <description>Source population from three human immunodeficiency virus (HIV)-infected patient cohorts: ICONA (Italian Cohort of Antiretroviral Naïve Patients), treatment naïve participants at initial presentation in Italy; HEPAVIH, HIV-hepatitis coinfected in France; MASTER (Management Standardizzato di Terapia Antiretrovirale), HIV-infected participants who are either treatment experienced or naïve patients in Italy</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Cohort - MASTER</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="72"/>
                    <measurement group_id="B5" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort - HEPAVIH</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort - ICONA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants positive for Hepatitis B and/or C at baseline</title>
          <description>Participant characteristics at baseline according to treatment group. Participants were tested for Hepatitis C antibody (HCV-Ab) and Hepatitis B surface antigen (HBs-Ag).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>HCV-Ab positive test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="82"/>
                    <measurement group_id="B5" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs-Ag positive test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants who were ART naïve at baseline</title>
          <description>Participant characteristics at baseline according to treatment group. The number of participants who had not received antiretroviral therapy (ART) was recorded.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="50"/>
                    <measurement group_id="B5" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants with acquired immunodeficiency syndrome (AIDS) at baseline</title>
          <description>Participant characteristics at baseline according to treatment group. The number of participants with AIDS was recorded.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants with the indicated alanine aminotransferase (ALT) levels at baseline</title>
          <description>Participant characteristics at baseline according to treatment group. The number of participants with the indicated ALT levels was recorded. IU/L = International Units per Liter.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Baseline ALT &lt;= 200 IU/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="83"/>
                    <measurement group_id="B5" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline ALT &gt; 200 IU/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline ALT Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Events of ALT Elevation After Baseline, Controlling for APRI Score and Other Variables</title>
        <description>An elevation in ALT is defined as a single value &gt;200 IU/I.</description>
        <time_frame>The incidence of these events was assessed over time during Year 1, censoring participants' follow-up at date of last ALT</time_frame>
        <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
        <group_list>
          <group group_id="O1">
            <title>ART naïve</title>
            <description>Patients that have never been exposed (termed naive) to Antiretroviral (ART) therapy</description>
          </group>
          <group group_id="O2">
            <title>Not ART naïve</title>
            <description>Patients who have previously been exposed to ART therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Events of ALT Elevation After Baseline, Controlling for APRI Score and Other Variables</title>
          <description>An elevation in ALT is defined as a single value &gt;200 IU/I.</description>
          <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <p_value_desc>Only variables showing an imbalance between the treatment groups (when possible and besides APRI score) were included. The following were also included, but p &gt; 0.05: APRI score, use of non-ARV drug, baseline CD4, platelets, and bilirubin.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>6.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.26</ci_lower_limit>
            <ci_upper_limit>29.46</ci_upper_limit>
            <estimate_desc>Confidence Interval and Hazard Ratio for &quot;ART naïve.&quot; &quot;Not ART naïve&quot; is the reference group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Events of an Elevation in ALT After Baseline by Treatment Group, Controlling for APRI-score, and Other Variables</title>
        <description>An elevation in ALT is defined as a single value &gt;200 IU/I.</description>
        <time_frame>Incidence of these events was assessed over time during Year 1, censoring patients' follow-up at date of last ALT</time_frame>
        <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
        <group_list>
          <group group_id="O1">
            <title>FPV 700 mg BID/RTV 100 mg BID</title>
            <description>Fosamprenavir 700 milligrams (mg) twice a day (BID)/Ritonavir 100 mg BID</description>
          </group>
          <group group_id="O2">
            <title>FPV 700 mg BID/RTV 100 mg QD</title>
            <description>FPV 700 mg BID/RTV 100 mg once a day (QD)</description>
          </group>
          <group group_id="O3">
            <title>LPV, Standard Dose</title>
            <description>Lopinavir (LPV), Standard Dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Events of an Elevation in ALT After Baseline by Treatment Group, Controlling for APRI-score, and Other Variables</title>
          <description>An elevation in ALT is defined as a single value &gt;200 IU/I.</description>
          <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <p_value_desc>Only variables showing an imbalance between the treatment groups (when possible and besides APRI score) were included. The following were also included, but p &gt; 0.05: APRI score, use of non-ARV drug, baseline CD4, platelets, and bilirubin.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>4.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>16.50</ci_upper_limit>
            <estimate_desc>Confidence Interval and Hazard Ratio for &quot;FPV 700 mg BID/RTV 100 mg BID.&quot; &quot;LPV&quot; is the reference group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.68</p_value>
            <p_value_desc>Only variables showing an imbalance between the treatment groups (when possible and besides APRI score) were included. The following were also included, but p &gt; 0.05: APRI score, use of non-ARV drug, baseline CD4, platelets, and bilirubin.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.16</ci_lower_limit>
            <ci_upper_limit>16.27</ci_upper_limit>
            <estimate_desc>Confidence Interval and Hazard Ratio for &quot;FPV 700 mg BID/RTV 100 mg QD.&quot; &quot;LPV&quot; is the reference group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Events of an Elevation in ALT After Baseline by Treatment Group, Controlling for FIB-score, and Other Variables</title>
        <description>An elevation in ALT is defined as a single value &gt;200 IU/I.</description>
        <time_frame>Incidence was assessed over time during Year 1</time_frame>
        <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
        <group_list>
          <group group_id="O1">
            <title>FPV 700 mg BID/RTV 100 mg BID</title>
            <description>Fosamprenavir 700 milligrams (mg) twice a day (BID)/Ritonavir 100 mg BID</description>
          </group>
          <group group_id="O2">
            <title>FPV 700 mg BID/RTV 100 mg QD</title>
            <description>FPV 700 mg BID/RTV 100 mg once a day (QD)</description>
          </group>
          <group group_id="O3">
            <title>LPV, Standard Dose</title>
            <description>Lopinavir (LPV), Standard Dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Events of an Elevation in ALT After Baseline by Treatment Group, Controlling for FIB-score, and Other Variables</title>
          <description>An elevation in ALT is defined as a single value &gt;200 IU/I.</description>
          <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.17</p_value>
            <p_value_desc>Only variables showing an imbalance between the treatment groups (when possible) were included. The following were also included, but p &gt; 0.05: APRI score, use of non-ARV drug, baseline CD4, platelets, and bilirubin.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>12.36</ci_upper_limit>
            <estimate_desc>Confidence Interval and Hazard Ratio for &quot;FPV 700 mg BID/RTV 100 mg BID.&quot; &quot;LPV&quot; is the reference group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.85</p_value>
            <p_value_desc>Only variables showing an imbalance between the treatment groups (when possible) were included. The following were also included, but p &gt; 0.05: APRI score, use of non-ARV drug, baseline CD4, platelets, and bilirubin.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.12</ci_lower_limit>
            <ci_upper_limit>13.33</ci_upper_limit>
            <estimate_desc>Confidence Interval and Hazard Ratio for &quot;FPV 700 mg BID/RTV 100 mg QD.&quot; &quot;LPV&quot; is the reference group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Events of an Elevation in ALT After Baseline by Treatment Group, Controlling for Current Values of CD4 and Platelet Counts</title>
        <description>An elevation in ALT is defined as a single value &gt;200 IU/I.</description>
        <time_frame>Incidence was assessed over time during Year 1</time_frame>
        <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
        <group_list>
          <group group_id="O1">
            <title>FPV 700 mg BID/RTV 100 mg BID</title>
            <description>Fosamprenavir 700 milligrams (mg) twice a day (BID)/Ritonavir 100 mg BID</description>
          </group>
          <group group_id="O2">
            <title>FPV 700 mg BID/RTV 100 mg QD</title>
            <description>FPV 700 mg BID/RTV 100 mg once a day (QD)</description>
          </group>
          <group group_id="O3">
            <title>LPV, Standard Dose</title>
            <description>Lopinavir (LPV), Standard Dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Events of an Elevation in ALT After Baseline by Treatment Group, Controlling for Current Values of CD4 and Platelet Counts</title>
          <description>An elevation in ALT is defined as a single value &gt;200 IU/I.</description>
          <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <p_value_desc>Only variables showing an imbalance between the treatment groups (when possible and besides APRI score) were included. The following were also included, but p &gt; 0.05: APRI score, use of non-ARV drug, baseline CD4, platelets, and bilirubin.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>3.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>10.82</ci_upper_limit>
            <estimate_desc>Confidence Interval and Hazard Ratio for &quot;FPV 700 mg BID/RTV 100 mg BID.&quot; &quot;LPV&quot; is the reference group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.96</p_value>
            <p_value_desc>Only variables showing an imbalance between the treatment groups (when possible and besides APRI score) were included. The following were also included, but p &gt; 0.05: APRI score, use of non-ARV drug, baseline CD4, platelets, and bilirubin.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.11</ci_lower_limit>
            <ci_upper_limit>9.83</ci_upper_limit>
            <estimate_desc>Confidence Interval and Hazard Ratio for &quot;FPV 700 mg BID/RTV 100 mg QD.&quot; &quot;LPV&quot; is the reference group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Events of First Discontinuation of FPV/RTV or LPV/RTV Alone by Treatment Group, Controlling for APRI-score, and Other Variables</title>
        <description>A first discontinuation is defined as the first occurrence of stopping FPV/RTV or LPV/RTV.</description>
        <time_frame>Incidence was assessed over time during Year 1</time_frame>
        <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
        <group_list>
          <group group_id="O1">
            <title>FPV 700 mg BID/RTV 100 mg BID</title>
            <description>Fosamprenavir 700 milligrams (mg) twice a day (BID)/Ritonavir 100 mg BID</description>
          </group>
          <group group_id="O2">
            <title>FPV 700 mg BID/RTV 100 mg QD</title>
            <description>FPV 700 mg BID/RTV 100 mg once a day (QD)</description>
          </group>
          <group group_id="O3">
            <title>FPV, Other</title>
            <description>All other dosages of Fosamprenavir</description>
          </group>
          <group group_id="O4">
            <title>LPV, Standard Dose</title>
            <description>Lopinavir (LPV), Standard Dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Events of First Discontinuation of FPV/RTV or LPV/RTV Alone by Treatment Group, Controlling for APRI-score, and Other Variables</title>
          <description>A first discontinuation is defined as the first occurrence of stopping FPV/RTV or LPV/RTV.</description>
          <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.57</p_value>
            <p_value_desc>Variables showing imbalance between treatments (when possible and besides APRI score) were included. Gender, mode of HIV transmission, ART naive, APRI score, use of non-ARV drug, baseline CD4, platelets, and bilirubin were also included, but p&gt;0.05.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>3.31</ci_upper_limit>
            <estimate_desc>Confidence Interval and Hazard Ratio for &quot;FPV 700 mg BID/RTV 100 mg BID.&quot; &quot;LPV&quot; is the reference group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.22</p_value>
            <p_value_desc>Variables showing imbalance between treatments (when possible and besides APRI score) were included. Gender, mode of HIV transmission, ART naive, APRI score, use of non-ARV drug, baseline CD4, platelets, and bilirubin were also included, but p&gt;0.05.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.04</ci_lower_limit>
            <ci_upper_limit>2.14</ci_upper_limit>
            <estimate_desc>Confidence Interval and Hazard Ratio for &quot;FPV 700 mg BID/RTV 100 mg QD.&quot; &quot;LPV&quot; is the reference group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.47</p_value>
            <p_value_desc>Variables showing imbalance between treatments (when possible and besides APRI score) were included. Gender, mode of HIV transmission, ART naive, APRI score, use of non-ARV drug, baseline CD4, platelets, and bilirubin were also included, but p&gt;0.05.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>9.91</ci_upper_limit>
            <estimate_desc>Confidence Interval and Hazard Ratio for &quot;FPV, Other.&quot; &quot;LPV&quot; is the reference group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Events of First Discontinuation of FPV/RTV or LPV/RTV Alone by Treatment Group, Controlling for FIB-score, and Other Variables</title>
        <description>A first discontinuation is defined as the first occurrence of stopping FPV/RTV or LPV/RTV.</description>
        <time_frame>Incidence was assessed over time during Year 1</time_frame>
        <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
        <group_list>
          <group group_id="O1">
            <title>FPV 700 mg BID/RTV 100 mg BID</title>
            <description>Fosamprenavir 700 milligrams (mg) twice a day (BID)/Ritonavir 100 mg BID</description>
          </group>
          <group group_id="O2">
            <title>FPV 700 mg BID/RTV 100 mg QD</title>
            <description>FPV 700 mg BID/RTV 100 mg once a day (QD)</description>
          </group>
          <group group_id="O3">
            <title>FPV, Other</title>
            <description>All other dosages of Fosamprenavir</description>
          </group>
          <group group_id="O4">
            <title>LPV, Standard Dose</title>
            <description>Lopinavir (LPV), Standard Dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Events of First Discontinuation of FPV/RTV or LPV/RTV Alone by Treatment Group, Controlling for FIB-score, and Other Variables</title>
          <description>A first discontinuation is defined as the first occurrence of stopping FPV/RTV or LPV/RTV.</description>
          <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.48</p_value>
            <p_value_desc>Only variables showing imbalance between treatments (when possible) were included. The following were also included, but p &gt; 0.05: gender, mode of HIV transmission, ART naive, APRI score, use of non-ARV drug, baseline CD4, platelets, and bilirubin.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>3.55</ci_upper_limit>
            <estimate_desc>Confidence Interval and Hazard Ratio for &quot;FPV 700 mg BID/RTV 100 mg BID.&quot; &quot;LPV&quot; is the reference group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.23</p_value>
            <p_value_desc>Only variables showing imbalance between treatments (when possible) were included. The following were also included, but p &gt; 0.05: gender, mode of HIV transmission, ART naive, APRI score, use of non-ARV drug, baseline CD4, platelets, and bilirubin.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.03</ci_lower_limit>
            <ci_upper_limit>2.18</ci_upper_limit>
            <estimate_desc>Confidence Interval and Hazard Ratio for &quot;FPV 700 mg BID/RTV 100 mg QD.&quot; &quot;LPV&quot; is the reference group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.56</p_value>
            <p_value_desc>Only variables showing imbalance between treatments (when possible) were included. The following were also included, but p &gt; 0.05: gender, mode of HIV transmission, ART naive, APRI score, use of non-ARV drug, baseline CD4, platelets, and bilirubin.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.29</ci_lower_limit>
            <ci_upper_limit>9.47</ci_upper_limit>
            <estimate_desc>Confidence Interval and Hazard Ratio for &quot;FPV, Other.&quot; &quot;LPV&quot; is the reference group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Median Length of Participant Follow-up and Length of Time on Antiretroviral Therapy (ART) at Baseline</title>
        <description>Participant characteristics at baseline are presented according to treatment group. ART is used for the treatment of HIV.</description>
        <time_frame>Baseline</time_frame>
        <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
        <group_list>
          <group group_id="O1">
            <title>FPV 700 mg BID/RTV 100 mg BID</title>
            <description>Fosamprenavir 700 milligrams (mg) twice a day (BID)/Ritonavir 100 mg BID</description>
          </group>
          <group group_id="O2">
            <title>FPV 700 mg BID/RTV 100 mg QD</title>
            <description>FPV 700 mg BID/RTV 100 mg once a day (QD)</description>
          </group>
          <group group_id="O3">
            <title>FPV, Other</title>
            <description>All other dosages of Fosamprenavir</description>
          </group>
          <group group_id="O4">
            <title>LPV, Standard Dose</title>
            <description>Lopinavir (LPV), Standard Dose</description>
          </group>
        </group_list>
        <measure>
          <title>Median Length of Participant Follow-up and Length of Time on Antiretroviral Therapy (ART) at Baseline</title>
          <description>Participant characteristics at baseline are presented according to treatment group. ART is used for the treatment of HIV.</description>
          <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Length of follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" lower_limit="0.07" upper_limit="1.07"/>
                    <measurement group_id="O2" value="0.36" lower_limit="0.04" upper_limit="1.02"/>
                    <measurement group_id="O3" value="0.95" lower_limit="0.6" upper_limit="1.50"/>
                    <measurement group_id="O4" value="0.34" lower_limit="0.12" upper_limit="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tiime on ART</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0" upper_limit="12"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0" upper_limit="11"/>
                    <measurement group_id="O3" value="3.21" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="O4" value="0.08" lower_limit="0" upper_limit="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Events of First Discontinuation of FPV/RTV- or LPV/RTV Alone by Treatment Group, Controlling for Current Values of CD4 and Platelet Counts</title>
        <description>A first discontinuation is defined as the first occurrence of stopping FPV/RTV or LPV/RTV</description>
        <time_frame>Incidence was assessed over time during Year 1</time_frame>
        <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
        <group_list>
          <group group_id="O1">
            <title>FPV 700 mg BID/RTV 100 mg BID</title>
            <description>Fosamprenavir 700 milligrams (mg) twice a day (BID)/Ritonavir 100 mg BID</description>
          </group>
          <group group_id="O2">
            <title>FPV 700 mg BID/RTV 100 mg QD</title>
            <description>Fosamprenavir 700 mg BID/Ritonavir 100 mg once a day (QD)</description>
          </group>
          <group group_id="O3">
            <title>FPV, Other</title>
            <description>All other dosages of Fosamprenavir</description>
          </group>
          <group group_id="O4">
            <title>LPV, Standard Dose</title>
            <description>Lopinavir, Standard Dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Events of First Discontinuation of FPV/RTV- or LPV/RTV Alone by Treatment Group, Controlling for Current Values of CD4 and Platelet Counts</title>
          <description>A first discontinuation is defined as the first occurrence of stopping FPV/RTV or LPV/RTV</description>
          <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.72</p_value>
            <p_value_desc>Only variables showing an imbalance between treatment groups were included: gender, mode of HIV transmission, ART naive, use of non-ARV drug, baseline bilirubin.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>2.66</ci_upper_limit>
            <estimate_desc>Confidence Interval and Hazard Ratio for &quot; FPV 700 mg BID/RTV 100 mg BID&quot;. &quot;LPV&quot; is the reference group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.21</p_value>
            <p_value_desc>Only variables showing an imbalance between treatment groups were included: gender, mode of HIV transmission, ART naive, use of non-ARV drug, baseline bilirubin.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.03</ci_lower_limit>
            <ci_upper_limit>2.08</ci_upper_limit>
            <estimate_desc>Confidence Interval and Hazard Ratio for &quot; FPV 700 mg BID/RTV 100 mg QD&quot;. &quot;LPV&quot; is the reference group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Only variables showing an imbalance between treatment groups were included: gender, mode of HIV transmission, ART naive, use of non-ARV drug, baseline bilirubin.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.15</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>6.97</ci_upper_limit>
            <estimate_desc>Confidence Interval and Hazard Ratio for &quot; FPV, other&quot;. &quot;LPV&quot; is the reference group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cluster of Differentiation (CD4) Count at Baseline</title>
        <description>Participant characteristics at baseline according to treatment group. CD4 count is a measurement of how many functional CD4 T-cells are circulating in the blood. The lower the absolute CD4 count, the weaker the immune system.</description>
        <time_frame>Baseline</time_frame>
        <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
        <group_list>
          <group group_id="O1">
            <title>FPV 700 mg BID/RTV 100 mg BID</title>
          </group>
          <group group_id="O2">
            <title>FPV 700 mg BID/RTV 100 mg QD</title>
            <description>Fosamprenavir 700 mg BID/Ritonavir 100 mg QD</description>
          </group>
          <group group_id="O3">
            <title>FPV, Other</title>
            <description>All other dosages of Fosamprenavir</description>
          </group>
          <group group_id="O4">
            <title>LPV, Standard Dose</title>
            <description>Lopinavir, Standard Dose</description>
          </group>
        </group_list>
        <measure>
          <title>Cluster of Differentiation (CD4) Count at Baseline</title>
          <description>Participant characteristics at baseline according to treatment group. CD4 count is a measurement of how many functional CD4 T-cells are circulating in the blood. The lower the absolute CD4 count, the weaker the immune system.</description>
          <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
          <units>cells/microliter (μl)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="355" lower_limit="66" upper_limit="1585"/>
                    <measurement group_id="O2" value="331" lower_limit="113" upper_limit="912"/>
                    <measurement group_id="O3" value="370" lower_limit="197" upper_limit="427"/>
                    <measurement group_id="O4" value="252" lower_limit="7" upper_limit="1113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Median Aspartate Aminotransferase (AST)-Platelet Ratio Index (APRI) Score at Baseline</title>
        <description>The APRI score (AST to platelet ratio index) is an index comprised of biochemical values and is used to determine the degree of hepatic fibrosis. It is calculated as follows: APRI score = ([AST level/Upper Limit Normal]/Platelet counts) x 100. AST = Aspartate aminotransferase. In general, APRI scores range from 0 to &gt;2.0, where scores &lt;0.5 indicate no significant fibrosis, scores &gt;1.5 indicate significant fibrosis, and scores &gt;2.0 have been shown to be best correlated with the presence of cirrhosis.</description>
        <time_frame>Baseline</time_frame>
        <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
        <group_list>
          <group group_id="O1">
            <title>FPV 700 mg BID/RTV 100 mg BID</title>
            <description>Fosamprenavir 700 mg BID/Ritonavir 100 mg BID</description>
          </group>
          <group group_id="O2">
            <title>FPV 700 mg BID/RTV 100 mg QD</title>
            <description>Fosamprenavir 700 mg BID/Ritonavir 100 mg QD</description>
          </group>
          <group group_id="O3">
            <title>FPV, Other</title>
            <description>All other dosages of Fosamprenavir</description>
          </group>
          <group group_id="O4">
            <title>LPV, Standard Dose</title>
            <description>Lopinavir, Standard Dose</description>
          </group>
        </group_list>
        <measure>
          <title>Median Aspartate Aminotransferase (AST)-Platelet Ratio Index (APRI) Score at Baseline</title>
          <description>The APRI score (AST to platelet ratio index) is an index comprised of biochemical values and is used to determine the degree of hepatic fibrosis. It is calculated as follows: APRI score = ([AST level/Upper Limit Normal]/Platelet counts) x 100. AST = Aspartate aminotransferase. In general, APRI scores range from 0 to &gt;2.0, where scores &lt;0.5 indicate no significant fibrosis, scores &gt;1.5 indicate significant fibrosis, and scores &gt;2.0 have been shown to be best correlated with the presence of cirrhosis.</description>
          <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
          <units>APRI Score</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0.06" upper_limit="1.73"/>
                    <measurement group_id="O2" value="0.53" lower_limit="0.12" upper_limit="3.33"/>
                    <measurement group_id="O3" value="0.69" lower_limit="0.14" upper_limit="8.06"/>
                    <measurement group_id="O4" value="0.35" lower_limit="0.06" upper_limit="5.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Median FIB (a Model of End-stage Liver Disease) Score at Baseline</title>
        <description>The FIB-4 score is an index that combines biochemical values (platelets, ALT, AST) and age to determine the degree of hepatic fibrosis. FIB-4 = (Age x AST)/(Platelet counts x ALT1/2). The FIB-4 score ranges between values of 0 to 13. A score of &lt;1.45 indicates no/moderate fibrosis (F0-F1-F2-F3 in the ISHAK classification of fibrosis), whereas a score &gt;3.25 is indicative of extensive fibrosis or cirrhosis (F4-F5-F6). The ISHAK classification of fibrosis is a commonly used scoring system that stages fibrosis from 0-6 (1-2, portal fibrotic expansion; 3-4, bridging fibrosis; 5-6, cirrhosis).</description>
        <time_frame>Baseline</time_frame>
        <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
        <group_list>
          <group group_id="O1">
            <title>FPV 700 mg BID/RTV 100 mg BID</title>
            <description>Fosamprenavir 700 mg BID/Ritonavir 100 mg BID</description>
          </group>
          <group group_id="O2">
            <title>FPV 700 mg BID/RTV 100 mg QD</title>
            <description>Fosamprenavir 700 mg BID/Ritonavir 100 mg QD</description>
          </group>
          <group group_id="O3">
            <title>FPV, Other</title>
            <description>All other dosages of Fosamprenavir</description>
          </group>
          <group group_id="O4">
            <title>LPV, Standard Dose</title>
            <description>Lopinavir, Standard Dose</description>
          </group>
        </group_list>
        <measure>
          <title>Median FIB (a Model of End-stage Liver Disease) Score at Baseline</title>
          <description>The FIB-4 score is an index that combines biochemical values (platelets, ALT, AST) and age to determine the degree of hepatic fibrosis. FIB-4 = (Age x AST)/(Platelet counts x ALT1/2). The FIB-4 score ranges between values of 0 to 13. A score of &lt;1.45 indicates no/moderate fibrosis (F0-F1-F2-F3 in the ISHAK classification of fibrosis), whereas a score &gt;3.25 is indicative of extensive fibrosis or cirrhosis (F4-F5-F6). The ISHAK classification of fibrosis is a commonly used scoring system that stages fibrosis from 0-6 (1-2, portal fibrotic expansion; 3-4, bridging fibrosis; 5-6, cirrhosis).</description>
          <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
          <units>FIB Score</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" lower_limit="0.17" upper_limit="3.00"/>
                    <measurement group_id="O2" value="0.64" lower_limit="0.18" upper_limit="5.87"/>
                    <measurement group_id="O3" value="1.96" lower_limit="0.25" upper_limit="13.47"/>
                    <measurement group_id="O4" value="0.74" lower_limit="0.19" upper_limit="4.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Median Model of End-stage Liver Disease (MELD) Score at Baseline</title>
        <description>MELD is a scoring system for assessing the severity of chronic liver disease and is used to predict participant survival. It is calculated using biochemical values as follows: MELD = (0.957 x Log[Creatinine]) + (0.378 x Log[Bilirubin]) + (1.120 x Log[INR]) + 0.6431. INR = International Normalized Ratio for prothrombin time. MELD scores range between 0 and 40, with 40 being the most severe, i.e., 100% mortality. In interpreting the MELD score in hospitalized participants, the 3-month mortality is: score &gt;=40, 100% mortality; 30–39, 83% mortality; 20–29, 76% mortality; 10–19, 27% mortality.</description>
        <time_frame>Baseline</time_frame>
        <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe. MELD scores are not available for the “FPV 700 mg BID/RTV 100 mg QD” group due to missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>FPV 700 mg BID/RTV 100 mg BID</title>
            <description>Fosamprenavir 700 mg BID/Ritonavir 100 mg BID</description>
          </group>
          <group group_id="O2">
            <title>FPV 700 mg BID/RTV 100 mg QD</title>
            <description>Fosamprenavir 700 mg BID/Ritonavir 100 mg QD</description>
          </group>
          <group group_id="O3">
            <title>FPV, Other</title>
            <description>All other dosages of Fosamprenavir</description>
          </group>
          <group group_id="O4">
            <title>LPV, Standard Dose</title>
            <description>Lopinavir, Standard Dose</description>
          </group>
        </group_list>
        <measure>
          <title>Median Model of End-stage Liver Disease (MELD) Score at Baseline</title>
          <description>MELD is a scoring system for assessing the severity of chronic liver disease and is used to predict participant survival. It is calculated using biochemical values as follows: MELD = (0.957 x Log[Creatinine]) + (0.378 x Log[Bilirubin]) + (1.120 x Log[INR]) + 0.6431. INR = International Normalized Ratio for prothrombin time. MELD scores range between 0 and 40, with 40 being the most severe, i.e., 100% mortality. In interpreting the MELD score in hospitalized participants, the 3-month mortality is: score &gt;=40, 100% mortality; 30–39, 83% mortality; 20–29, 76% mortality; 10–19, 27% mortality.</description>
          <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe. MELD scores are not available for the “FPV 700 mg BID/RTV 100 mg QD” group due to missing data.</population>
          <units>MELD score</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.11" lower_limit="-4" upper_limit="11.85"/>
                    <measurement group_id="O3" value="6.56" lower_limit="5.06" upper_limit="8.08"/>
                    <measurement group_id="O4" value="2.45" lower_limit="-6" upper_limit="22.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Median ALT and AST Scores at Baseline</title>
        <description>Participants characteristics at baseline according to treatment group.</description>
        <time_frame>Baseline</time_frame>
        <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
        <group_list>
          <group group_id="O1">
            <title>FPV 700 mg BID/RTV 100 mg BID</title>
            <description>Fosamprenavir 700 mg BID/Ritonavir 100 mg BID</description>
          </group>
          <group group_id="O2">
            <title>FPV 700 mg BID/RTV 100 mg QD</title>
            <description>Fosamprenavir 700 mg BID/Ritonavir 100 mg QD</description>
          </group>
          <group group_id="O3">
            <title>FPV, Other</title>
            <description>All other dosages of Fosamprenavir</description>
          </group>
          <group group_id="O4">
            <title>LPV, Standard Dose</title>
            <description>Lopinavir, Standard Dose</description>
          </group>
        </group_list>
        <measure>
          <title>Median ALT and AST Scores at Baseline</title>
          <description>Participants characteristics at baseline according to treatment group.</description>
          <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
          <units>IU/L (International Units per Liter)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64" lower_limit="10" upper_limit="282"/>
                    <measurement group_id="O2" value="53" lower_limit="28" upper_limit="297"/>
                    <measurement group_id="O3" value="64" lower_limit="37" upper_limit="568"/>
                    <measurement group_id="O4" value="52.5" lower_limit="7" upper_limit="416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" lower_limit="16" upper_limit="163"/>
                    <measurement group_id="O2" value="71" lower_limit="24" upper_limit="291"/>
                    <measurement group_id="O3" value="66" lower_limit="27" upper_limit="157"/>
                    <measurement group_id="O4" value="45" lower_limit="16" upper_limit="358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Events of First Discontinuation of FPV/RTV or LPV/RTV Alone Due to Adverse Events Only</title>
        <description>A first discontinuation is defined as the first occurrence of stopping FPV/RTV or LPV/RTV; where the reason for stopping is attritubed to adverse events only</description>
        <time_frame>Incidence was assessed over time during Year 1</time_frame>
        <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
        <group_list>
          <group group_id="O1">
            <title>FPV 700 mg BID/RTV 100 mg BID</title>
            <description>Fosamprenavir 700 milligrams (mg) twice a day (BID)/Ritonavir 100 mg BID</description>
          </group>
          <group group_id="O2">
            <title>LPV, Standard Dose</title>
            <description>Lopinavir, Standard Dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Events of First Discontinuation of FPV/RTV or LPV/RTV Alone Due to Adverse Events Only</title>
          <description>A first discontinuation is defined as the first occurrence of stopping FPV/RTV or LPV/RTV; where the reason for stopping is attritubed to adverse events only</description>
          <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.10</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>3.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>18.05</ci_upper_limit>
            <estimate_desc>Confidence Interval and Hazard Ratio for &quot; FPV 700 mg BID/RTV 100 mg BID&quot;. &quot;LPV&quot; is the reference group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Events of First Discontinuation of One or More Drugs Included in the FPV/RTV- or LPV/RTV-based Regimen by Treatment Group, Controlling for APRI-score and Other Variables (See Comments)</title>
        <description>A first discontinuation is defined as the first occurrence of stopping one or more drugs in the FPV/RTV or LPV/RTV-based regime</description>
        <time_frame>Incidence was assessed over time during Year 1</time_frame>
        <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
        <group_list>
          <group group_id="O1">
            <title>FPV 700 mg BID/RTV 100 mg BID</title>
            <description>Fosamprenavir 700 milligrams (mg) twice a day (BID)/Ritonavir 100 mg BID</description>
          </group>
          <group group_id="O2">
            <title>FPV 700 mg BID/RTV 100 mg QD</title>
            <description>Fosamprenavir 700 mg BID/Ritonavir 100 mg once a day (QD)</description>
          </group>
          <group group_id="O3">
            <title>FPV, Other</title>
            <description>All other dosages of Fosamprenavir</description>
          </group>
          <group group_id="O4">
            <title>LPV, Standard Dose</title>
            <description>Lopinavir, Standard Dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Events of First Discontinuation of One or More Drugs Included in the FPV/RTV- or LPV/RTV-based Regimen by Treatment Group, Controlling for APRI-score and Other Variables (See Comments)</title>
          <description>A first discontinuation is defined as the first occurrence of stopping one or more drugs in the FPV/RTV or LPV/RTV-based regime</description>
          <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <p_value_desc>Only variables showing an imbalance between the treatment groups were included, but p &gt; .05: gender, mode of HIV transmission, ART naive, APRI score, baseline use of non-ARV drug, and baseline values of CD4, platelets and bilirubin.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.16</ci_lower_limit>
            <ci_upper_limit>5.54</ci_upper_limit>
            <estimate_desc>Confidence Interval and Hazard Ratio for &quot; FPV 700 mg BID/RTV 100 mg BID&quot;. &quot;LPV&quot; is the reference group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <p_value_desc>Only variables showing an imbalance between the treatment groups were included, but p &gt; .05: gender, mode of HIV transmission, ART naive, APRI score, baseline use of non-ARV drug, and baseline values of CD4, platelets and bilirubin.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>4.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.54</ci_lower_limit>
            <ci_upper_limit>11.27</ci_upper_limit>
            <estimate_desc>Confidence Interval and Hazard Ratio for &quot; FPV 700 mg BID/RTV 100 mg QD&quot;. &quot;LPV&quot; is the reference group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <p_value_desc>Only variables showing an imbalance between the treatment groups were included, but p &gt; .05: gender, mode of HIV transmission, ART naive, APRI score, baseline use of non-ARV drug, and baseline values of CD4, platelets and bilirubin.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>3.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>13.90</ci_upper_limit>
            <estimate_desc>Confidence Interval and Hazard Ratio for &quot; FPV, other&quot;. &quot;LPV&quot; is the reference group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Events of First Discontinuation of One or More Drugs Included in the FPV/RTV- or LPV/RTV-based Regimen by Treatment Group, Controlling for FIB-score and Other Variables</title>
        <description>A first discontinuation is defined as the first occurrence of stopping one or more drugs in the FPV/RTV or LPV/RTV-based regime.</description>
        <time_frame>Incidence was assessed over time during Year 1</time_frame>
        <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
        <group_list>
          <group group_id="O1">
            <title>FPV 700 mg BID/RTV 100 mg BID</title>
            <description>Fosamprenavir 700 milligrams (mg) twice a day (BID)/Ritonavir 100 mg BID</description>
          </group>
          <group group_id="O2">
            <title>FPV 700 mg BID/RTV 100 mg QD</title>
            <description>Fosamprenavir 700 mg BID/Ritonavir 100 mg once a day (QD)</description>
          </group>
          <group group_id="O3">
            <title>FPV, Other</title>
            <description>All other dosages of Fosamprenavir</description>
          </group>
          <group group_id="O4">
            <title>LPV, Standard Dose</title>
            <description>Lopinavir, Standard Dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Events of First Discontinuation of One or More Drugs Included in the FPV/RTV- or LPV/RTV-based Regimen by Treatment Group, Controlling for FIB-score and Other Variables</title>
          <description>A first discontinuation is defined as the first occurrence of stopping one or more drugs in the FPV/RTV or LPV/RTV-based regime.</description>
          <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <p_value_desc>Only variables showing an imbalance between the treatment groups were included: gender, mode of HIV transmission, ART naive, baseline use of non-ARV drug, and baseline values of CD4, platelets and bilirubin.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.21</ci_lower_limit>
            <ci_upper_limit>5.9</ci_upper_limit>
            <estimate_desc>Confidence Interval and Hazard Ratio for &quot; FPV 700 mg BID/RTV 100 mg BID&quot;. &quot;LPV&quot; is the reference group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <p_value_desc>Only variables showing an imbalance between the treatment groups were included: gender, mode of HIV transmission, ART naive, baseline use of non-ARV drug, and baseline values of CD4, platelets and bilirubin.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>4.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.61</ci_lower_limit>
            <ci_upper_limit>12.08</ci_upper_limit>
            <estimate_desc>Confidence Interval and Hazard Ratio for &quot; FPV 700 mg BID/RTV 100 mg QD&quot;. &quot;LPV&quot; is the reference group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.11</p_value>
            <p_value_desc>Only variables showing an imbalance between the treatment groups were included: gender, mode of HIV transmission, ART naive, baseline use of non-ARV drug, and baseline values of CD4, platelets and bilirubin.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>3.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>12.03</ci_upper_limit>
            <estimate_desc>Confidence Interval and Hazard Ratio for &quot; FPV, other&quot;. &quot;LPV&quot; is the reference group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Events of First Discontinuation of One or More Drugs Included in the FPV/RTV- or LPV/RTV-based Regimen by Treatment Group, Controlling Current Values of CD4 and Platelet Counts</title>
        <description>A first discontinuation is defined as the first occurrence of stopping one or more drugs in the FPV/RTV or LPV/RTV-based regime.</description>
        <time_frame>Incidence was assessed over time during Year 1</time_frame>
        <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
        <group_list>
          <group group_id="O1">
            <title>FPV 700 mg BID/RTV 100 mg BID</title>
            <description>Fosamprenavir 700 milligrams (mg) twice a day (BID)/Ritonavir 100 mg BID</description>
          </group>
          <group group_id="O2">
            <title>FPV 700 mg BID/RTV 100 mg QD</title>
            <description>Fosamprenavir 700 mg BID/Ritonavir 100 mg once a day (QD)</description>
          </group>
          <group group_id="O3">
            <title>FPV, Other</title>
            <description>All other dosages of Fosamprenavir</description>
          </group>
          <group group_id="O4">
            <title>LPV, Standard Dose</title>
            <description>Lopinavir, Standard Dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Events of First Discontinuation of One or More Drugs Included in the FPV/RTV- or LPV/RTV-based Regimen by Treatment Group, Controlling Current Values of CD4 and Platelet Counts</title>
          <description>A first discontinuation is defined as the first occurrence of stopping one or more drugs in the FPV/RTV or LPV/RTV-based regime.</description>
          <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <p_value_desc>Only variables showing an imbalance between the treatment groups were included: gender, mode of HIV transmission, ART naive, APRI-score, baseline use of non-ARV drug and baseline bilirubin.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.06</ci_lower_limit>
            <ci_upper_limit>4.15</ci_upper_limit>
            <estimate_desc>Confidence Interval and Hazard Ratio for &quot; FPV 700 mg BID/RTV 100 mg BID&quot;. &quot;LPV&quot; is the reference group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <p_value_desc>Only variables showing an imbalance between the treatment groups were included: gender, mode of HIV transmission, ART naive, APRI-score, baseline use of non-ARV drug and baseline bilirubin.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>3.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.48</ci_lower_limit>
            <ci_upper_limit>8.81</ci_upper_limit>
            <estimate_desc>Confidence Interval and Hazard Ratio for &quot; FPV 700 mg BID/RTV 100 mg QD&quot;. &quot;LPV&quot; is the reference group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.10</p_value>
            <p_value_desc>Only variables showing an imbalance between the treatment groups were included: gender, mode of HIV transmission, ART naive, APRI-score, baseline use of non-ARV drug and baseline bilirubin.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>6.32</ci_upper_limit>
            <estimate_desc>Confidence Interval and Hazard Ratio for &quot; FPV, other&quot;. &quot;LPV&quot; is the reference group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Events of Discontinuation of One or More Drugs in the FPV/RTV- or LPV/RTV Regimen Due to Adverse Events Only</title>
        <description>Defined as the occurrence of stopping FPV/RTV or LPV/RTV; where the reason for stopping is attributed to adverse events only</description>
        <time_frame>Incidence was assessed over time during Year 1</time_frame>
        <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
        <group_list>
          <group group_id="O1">
            <title>FPV 700 mg BID/RTV 100 mg BID</title>
            <description>Fosamprenavir 700 milligrams (mg) twice a day (BID)/Ritonavir 100 mg BID</description>
          </group>
          <group group_id="O2">
            <title>LPV, Standard Dose</title>
            <description>Lopinavir, Standard Dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Events of Discontinuation of One or More Drugs in the FPV/RTV- or LPV/RTV Regimen Due to Adverse Events Only</title>
          <description>Defined as the occurrence of stopping FPV/RTV or LPV/RTV; where the reason for stopping is attributed to adverse events only</description>
          <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>5.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.19</ci_lower_limit>
            <ci_upper_limit>22.02</ci_upper_limit>
            <estimate_desc>Confidence Interval and Hazard Ratio for &quot; FPV 700 mg BID/RTV 100 mg BID&quot;. &quot;LPV&quot; is the reference group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Events of First Discontinuation of FPV/RTV or LPV/RTV Alone Due to the Indicated Adverse Events</title>
        <description>Defined as the first occurrence of stopping FPV/RTV or LPV/RTV; where the reason for stopping is attributed to adverse events only. Adverse events can only be attributed to the body system stated (no further specificity is available).</description>
        <time_frame>Incidence was assessed over time during Year 1</time_frame>
        <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>All Participants, across all arms</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Events of First Discontinuation of FPV/RTV or LPV/RTV Alone Due to the Indicated Adverse Events</title>
          <description>Defined as the first occurrence of stopping FPV/RTV or LPV/RTV; where the reason for stopping is attributed to adverse events only. Adverse events can only be attributed to the body system stated (no further specificity is available).</description>
          <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hypersensitivity reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GI Tract</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pancreas</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nervous system</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kidneys</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other side effects (not specified as above)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Discontinued the Indicated Antiretrovirals for the First Time After Starting FPV/r or LPV/r</title>
        <description>Antiretrovirals discontinued for the first time after starting FPV/r or LPV/r</description>
        <time_frame>Assessed over time during Year 1</time_frame>
        <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
        <group_list>
          <group group_id="O1">
            <title>FPV 700 mg BID/RTV 100 mg BID</title>
            <description>Fosamprenavir 700 milligrams (mg) twice a day (BID)/Ritonavir 100 mg BID</description>
          </group>
          <group group_id="O2">
            <title>FPV 700 mg BID/RTV 100 mg QD</title>
            <description>Fosamprenavir 700 mg BID/Ritonavir 100 mg once a day (QD)</description>
          </group>
          <group group_id="O3">
            <title>FPV, Other</title>
            <description>All other dosages of Fosamprenavir</description>
          </group>
          <group group_id="O4">
            <title>LPV, Standard Dose</title>
            <description>Lopinavir, Standard Dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Discontinued the Indicated Antiretrovirals for the First Time After Starting FPV/r or LPV/r</title>
          <description>Antiretrovirals discontinued for the first time after starting FPV/r or LPV/r</description>
          <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ritonavir (full or booster)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lopinavir/r</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fos-amprenavir/r</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lamivudine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abacavir</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Combivir</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Truvada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atripla</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With the Indicated Major Reasons for Discontinuing One or More Drugs in the FPV/r or LPV/r Regimen</title>
        <description>Major reasons for discontinuing one or more drugs in the FPV/r or LPV/r regimen</description>
        <time_frame>Assessed over time during Year 1</time_frame>
        <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
        <group_list>
          <group group_id="O1">
            <title>FPV 700 mg BID/RTV 100 mg BID</title>
            <description>Fosamprenavir 700 milligrams (mg) twice a day (BID)/Ritonavir 100 mg BID</description>
          </group>
          <group group_id="O2">
            <title>FPV 700 mg BID/RTV 100 mg QD</title>
            <description>Fosamprenavir 700 mg BID/Ritonavir 100 mg once a day (QD)</description>
          </group>
          <group group_id="O3">
            <title>FPV, Other</title>
            <description>All other dosages of Fosamprenavir</description>
          </group>
          <group group_id="O4">
            <title>LPV, Standard Dose</title>
            <description>Lopinavir, Standard Dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Indicated Major Reasons for Discontinuing One or More Drugs in the FPV/r or LPV/r Regimen</title>
          <description>Major reasons for discontinuing one or more drugs in the FPV/r or LPV/r regimen</description>
          <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Virological failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypersensitivity reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxicity – GI tract</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxicity – Pancreas</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxicity, mainly from nervous system</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxicity, mainly from kidneys</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Side effects –any of the above unspecified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Co-morbidity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Simplified treatment available</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Structured Treatment Interruption (STI)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant’s wish/decision</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physician’s decision</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-compliance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other causes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown cause</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants for Which the Reason for Discontinuation of One or More Drugs in the FPV/RTV or LPV/RTV Regimen Was Due to Adverse Events Only</title>
        <description>Number of participants for which the reason for discontinuation of one or more drugs in the FPV/RTV or LPV/RTV regimen was due to adverse events only. Adverse events can only be attributed to the body system stated (no further specificity is available)</description>
        <time_frame>The incidence of these events was assessed over time during Year 1</time_frame>
        <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>All Participants, across all arms</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants for Which the Reason for Discontinuation of One or More Drugs in the FPV/RTV or LPV/RTV Regimen Was Due to Adverse Events Only</title>
          <description>Number of participants for which the reason for discontinuation of one or more drugs in the FPV/RTV or LPV/RTV regimen was due to adverse events only. Adverse events can only be attributed to the body system stated (no further specificity is available)</description>
          <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hypersensitivity reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GI Tract</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pancreas</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nervous system</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kidneys</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other side effects (not specified as above)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence Rates Per 100 Person-years of Follow-up (PYFU) of Study Main Outcome Measures</title>
        <description>Incidence rates per 100 person-years of follow-up of study primary outcome. The numbers analyzed in the category titles represent the number of patients with each event. Incidence rate is the number of new cases per population in a given time period, where the denominator is the sum of the person-time of the at-risk population.</description>
        <time_frame>Incidence of these events was assessed over time during Year 1</time_frame>
        <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>All Participants, across all arms</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rates Per 100 Person-years of Follow-up (PYFU) of Study Main Outcome Measures</title>
          <description>Incidence rates per 100 person-years of follow-up of study primary outcome. The numbers analyzed in the category titles represent the number of patients with each event. Incidence rate is the number of new cases per population in a given time period, where the denominator is the sum of the person-time of the at-risk population.</description>
          <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
          <units>incidence rate</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT elevations/flares after baseline, n=13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st stop of FPV/RTV or LPV/RTV alone, n=33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st stop &gt;=1 drug in FPV/RTV or LPV/RTV reg., n=53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe hepatic events, n=0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death or hospitalization due to AIDS, n=1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Median Blood Platelet Count at Baseline</title>
        <description>Participant characteristics at baseline according to treatment group.</description>
        <time_frame>Baseline</time_frame>
        <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
        <group_list>
          <group group_id="O1">
            <title>FPV 700 mg BID/RTV 100 mg BID</title>
            <description>Fosamprenavir 700 mg BID/Ritonavir 100 mg BID</description>
          </group>
          <group group_id="O2">
            <title>FPV 700 mg BID/RTV 100 mg QD</title>
            <description>Fosamprenavir 700 mg BID/Ritonavir 100 mg QD</description>
          </group>
          <group group_id="O3">
            <title>FPV, Other</title>
            <description>All other dosages of Fosamprenavir</description>
          </group>
          <group group_id="O4">
            <title>LPV, Standard Dose</title>
            <description>Lopinavir, Standard Dose</description>
          </group>
        </group_list>
        <measure>
          <title>Median Blood Platelet Count at Baseline</title>
          <description>Participant characteristics at baseline according to treatment group.</description>
          <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
          <units>10^9/liter</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180" lower_limit="45" upper_limit="327"/>
                    <measurement group_id="O2" value="146" lower_limit="24" upper_limit="246"/>
                    <measurement group_id="O3" value="145" lower_limit="44" upper_limit="222"/>
                    <measurement group_id="O4" value="167" lower_limit="39" upper_limit="396"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Median Bilirubin Level at Baseline</title>
        <description>Participant characteristics at baseline according to treatment group.</description>
        <time_frame>Baseline</time_frame>
        <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
        <group_list>
          <group group_id="O1">
            <title>FPV 700 mg BID/RTV 100 mg BID</title>
            <description>Fosamprenavir 700 mg BID/Ritonavir 100 mg BID</description>
          </group>
          <group group_id="O2">
            <title>FPV 700 mg BID/RTV 100 mg QD</title>
            <description>Fosamprenavir 700 mg BID/Ritonavir 100 mg QD</description>
          </group>
          <group group_id="O3">
            <title>FPV, Other</title>
            <description>All other dosages of Fosamprenavir</description>
          </group>
          <group group_id="O4">
            <title>LPV, Standard Dose</title>
            <description>Lopinavir, Standard Dose</description>
          </group>
        </group_list>
        <measure>
          <title>Median Bilirubin Level at Baseline</title>
          <description>Participant characteristics at baseline according to treatment group.</description>
          <population>HIV/hepatitis virus co-infected participants enrolled in a number of cohort studies in Europe</population>
          <units>milligrams (mg)/deciliter (dl)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" lower_limit="0.22" upper_limit="9.39"/>
                    <measurement group_id="O2" value="0.62" lower_limit="0.42" upper_limit="4.3"/>
                    <measurement group_id="O3" value="0.83" lower_limit="0.48" upper_limit="29.2"/>
                    <measurement group_id="O4" value="0.50" lower_limit="0.16" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>This is a retrospective study of pre-existing data; thus, no assessments for Serious or Non-serious Adverse Events were performed.</desc>
      <group_list>
        <group group_id="E1">
          <title>FPV 700 mg BID/RTV 100 mg BID</title>
          <description>Fosamprenavir 700 milligrams (mg) twice a day (BID)/Ritonavir 100 mg BID</description>
        </group>
        <group group_id="E2">
          <title>FPV 700 mg BID/RTV 100 mg QD</title>
          <description>FPV 700 mg BID/RTV 100 mg once a day (QD)</description>
        </group>
        <group group_id="E3">
          <title>FPV, Other</title>
          <description>All other dosages of Fosamprenavir</description>
        </group>
        <group group_id="E4">
          <title>LPV, Standard Dose</title>
          <description>Lopinavir (LPV), Standard Dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

